MedTrace Logo

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

NCT02921035 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 594

Last updated 2022-04-04

No results posted yet for this study

Summary

This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

DRUG

Rebif (Interferon beta-1a)

Rebif will be administered at a dose of 44 mcg, sc, tiw.

Sponsors & Collaborators

  • Merck Serono Middle East FZ LLC

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Merck Serono Middle East FZ-LLC · an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-07-27
Completion
2020-07-27

Countries

  • Algeria
  • Argentina
  • Bahrain
  • Bulgaria
  • Egypt
  • Hungary
  • Iran
  • Kuwait
  • Lebanon
  • Morocco
  • Poland
  • Saudi Arabia
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02921035 on ClinicalTrials.gov